EP2941255A4 - Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes - Google Patents

Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes

Info

Publication number
EP2941255A4
EP2941255A4 EP13870018.2A EP13870018A EP2941255A4 EP 2941255 A4 EP2941255 A4 EP 2941255A4 EP 13870018 A EP13870018 A EP 13870018A EP 2941255 A4 EP2941255 A4 EP 2941255A4
Authority
EP
European Patent Office
Prior art keywords
aggravated
microorganisms
treatment
disease caused
relieving symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13870018.2A
Other languages
German (de)
English (en)
Other versions
EP2941255A1 (fr
Inventor
Afif Mahmoud Ghannoum
Brian Vincent Sokol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arms Pharmaceutical LLC
Original Assignee
Arms Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arms Pharmaceutical LLC filed Critical Arms Pharmaceutical LLC
Publication of EP2941255A1 publication Critical patent/EP2941255A1/fr
Publication of EP2941255A4 publication Critical patent/EP2941255A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP13870018.2A 2013-01-04 2013-10-25 Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes Ceased EP2941255A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749195P 2013-01-04 2013-01-04
US201361829608P 2013-05-31 2013-05-31
US201361859960P 2013-07-30 2013-07-30
PCT/US2013/066863 WO2014107221A1 (fr) 2013-01-04 2013-10-25 Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes

Publications (2)

Publication Number Publication Date
EP2941255A1 EP2941255A1 (fr) 2015-11-11
EP2941255A4 true EP2941255A4 (fr) 2016-07-06

Family

ID=51062409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13870018.2A Ceased EP2941255A4 (fr) 2013-01-04 2013-10-25 Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes

Country Status (3)

Country Link
EP (1) EP2941255A4 (fr)
JP (1) JP6901824B2 (fr)
WO (1) WO2014107221A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US8992893B2 (en) 2011-04-19 2015-03-31 Arms Pharmaceutical, Llc Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
AU2015335907A1 (en) 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
EP3687375A4 (fr) * 2016-11-21 2022-01-19 Psomagen, Inc. Procédé et système pour caractériser une affection liée à une céphalée

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749869B1 (en) * 1997-09-26 2004-06-15 Ecolab Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
JP5189291B2 (ja) * 2003-11-07 2013-04-24 ヴァイラトックス， エルエルシー 塩化セチルピリジニウムの殺ウイルス活性
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
EP1871349A1 (fr) * 2005-04-11 2008-01-02 Nanobio Corporation Halogenures d'ammonium quaternaires pour le traitement de pathologies infectieuses
AU2008326386B2 (en) * 2007-11-21 2014-07-31 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
US8992893B2 (en) * 2011-04-19 2015-03-31 Arms Pharmaceutical, Llc Method of inhibiting harmful microorganisms and barrier-forming composition therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP2941255A1 (fr) 2015-11-11
WO2014107221A1 (fr) 2014-07-10
JP2016504381A (ja) 2016-02-12
JP6901824B2 (ja) 2021-07-14

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
IL266648B (en) A method for treating Parkinson's disease
IL243976A0 (en) kdm1a inhibitors for disease treatment
IL245193B (en) Thoracoscopic methods for the treatment of bronchial disease
HK1212972A1 (zh) 作爲 -蛋白抑制劑用於治療過度增殖性疾病的吡咯並-和吡唑並-三唑並二氮雜卓
IL244042A0 (en) A method for treating leiftic disease
EP2968321A4 (fr) Composés pour le traitement de maladies de fibrose
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2941255A4 (fr) Méthode permettant de traiter une maladie provoquée ou aggravée par des micro-organismes ou d'en soulager les symptômes
HK1216504A1 (zh) 疾病的治療方法
IL241096A0 (en) Treatment methods
GB201308466D0 (en) Improved process for treatment of minewater
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
SG10201802808SA (en) Method of treating ocular disorders
IL241482A0 (en) A method for treating Parkinson's disease
EP2911662A4 (fr) Procédé de traitement d'une maladie
GB201321628D0 (en) Treatment of disease
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GHANNOUM, AFIF, MAHMOUD

Inventor name: SOKOL, BRIAN, VINCENT

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160608

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/736 20060101AFI20160602BHEP

Ipc: A61K 31/155 20060101ALI20160602BHEP

Ipc: A61P 31/00 20060101ALI20160602BHEP

Ipc: A61K 31/047 20060101ALI20160602BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180226

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20220604